Large-Cap Injectable-Focused Pharma Company Gains USFDA Nod for Key Pain Management Drug Large-Cap Injectable-Focused Pharma Company Gains USFDA Nod for Key Pain Management Drug With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent. DSIJ Intelligence / Friday, April 4, 2025 0 188 Article rating: 5.0 With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent. Read more